Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells

We investigated the antiproliferative effects of four structurally similar prenylated xanthones, α-mangostin, β-mangostin, γ-mangostin, and methoxy-β-mangostin, in human colon cancer DLD-1 cells. We investigated the antiproliferative effects of four structurally similar prenylated xanthones, α-mango...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry 2005-11, Vol.13 (21), p.6064-6069
Hauptverfasser: Matsumoto, Kenji, Akao, Yukihiro, Ohguchi, Kenji, Ito, Tetsuro, Tanaka, Toshiyuki, Iinuma, Munekazu, Nozawa, Yoshinori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We investigated the antiproliferative effects of four structurally similar prenylated xanthones, α-mangostin, β-mangostin, γ-mangostin, and methoxy-β-mangostin, in human colon cancer DLD-1 cells. We investigated the antiproliferative effects of four structurally similar prenylated xanthones, α-mangostin, β-mangostin, γ-mangostin, and methoxy-β-mangostin, in human colon cancer DLD-1 cells. These xanthones differ in the number of hydroxyl and methoxy groups. Except for methoxy-β-mangostin, the other three xanthones strongly inhibited cell growth at 20 μM and their antitumor efficacy was correlated with the number of hydroxyl groups. Hoechst 33342 nuclear staining and nucleosomal DNA-gel electrophoresis revealed that the antiproliferative effects of α- and γ-mangostin, but not that of β-mangostin, were associated with apoptosis. It was also shown that their antiproliferative effects were associated with cell-cycle arrest by affecting the expression of cyclins, cdc2, and p27; G1 arrest was by α-mangostin and β-mangostin, and S arrest by γ-mangostin. These findings provide a relevant basis for the development of xanthones as an agent for cancer prevention and combination therapy with anti-cancer drugs.
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2005.06.065